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A B S T R A C T
Background: The long-term prognostic signiﬁcance of in-hospital worsening renal function (WRF) during
treatment of acute cardiac decompensation (ACD) remains controversial.
Methods: We analyzed data from 100 patients (mean age = 75 years; 53% men) presenting with ACD, in
whom the serum cystatin C (Cys-C) concentration was measured upon admission to the hospital and
4 days later.We examined the relationship between changes in Cys-C and primary study endpoint of risk
of death and re-hospitalization for management of ACD, up to 180 days, searched for predictors by
multiple variable analysis and calculated the hazard ratios (HR) and 95% conﬁdence intervals (CI).
Results: Amedian (25th to 75th percentile) increase in Cys-C from 1.29 (0.88–1.66) mg/l on day 1 to 1.31
(1.00–1.84) mg/l on day 4, observed in 66% of all patients, was associated with a signiﬁcant decrease
(p = 0.040) in the 180-day incidence of primary study endpoint. Bymultiple variable regression analysis,
an increase in Cys-C was an independent predictor of death and re-hospitalization for management of
ACD (HR 0.415; 95% CI 0.193–0.885; p = 0.023).
Conclusions: An increase in serum Cys-C concentration after hospitalization formanagement of ACDwas
associated with a decreased, long-term incidence of primary study endpoint.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Acute cardiac decompensation (ACD) is themost frequent cause
of hospitalization in the Western world [1,2]. Its pathophysiology
is being abundantly studied with a view to lower the high re-
hospitalization rates and mortality associated with it. The
pathologic interaction between heart and kidney, also known as
cardio-renal syndrome, is one of the greatest therapeutic
challenges [3,4]. Worsening renal function (WRF), deﬁned as a
>0.3 mg/dl increase in serum creatinine concentration, occurs in
approximately 25% of patients admitted to hospital for manage-
ment of ACD [5,6]. Although themechanisms ofWRF have not been
completely clariﬁed, a low cardiac output, elevation of the central
blood pressure, renin–aldosterone–angiotensin axis dysfunction,
sympathetic hyperactivity, oxidative injury, and a reduced renal* Corresponding author at: Department of Cardiovascular Medicine,
Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashidaimotsu, Amagasaki,
Hyogo 660-0828, Japan. Tel.: +81 78 6482 1521; fax: +81 78 6482 7430.
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsperfusion are important contributing factors [4]. In previous
studies, WRF has been associated with a high mortality and re-
hospitalization rate [5,7]. However, several recent studies are
conﬂicting with this observation and the prognostic value of in-
hospital WRF remains contentious [8–14].
Although various markers have been identiﬁed as potential
contributors to the cardio-renal syndrome in the past decade,
nearly all studies have deﬁned in-hospital WRF as a rise in serum
creatinine or in estimated glomerular ﬁltration rate (eGFR)
calculated from it. Cystatin-C (Cys-C) is a recently described
marker of renal function [16,17]. Its serum concentration is not
modiﬁed by age, gender, race, ormusclemass, and changes in eGFR
could be more accurately and rapidly detected with Cys-C than
with creatinine [18,19]. Cys-C is also a better predictor of mortality
and adverse cardiovascular events than serum creatinine-based
estimates in acute and chronic heart failure [20–23]. However, the
changes in Cys-C during hospitalization for ACD and its prognostic
contribution have rarely been reported and are controversial
[24–26]. This observational study examined the changes in Cys-C
during treatment of ACD, its associations with other factors, and its
prognostic contribution in patients presenting with ACD.reserved.
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We studied 100 Japanese patients admitted to our hospital
between February 2009 and March 2012 for management of ACD
diagnosed based on the typical symptoms and signs such as
dyspnea at rest or minimal effort with signs of pulmonary and/or
peripheral congestion, chest radiograph, 12-lead electrocardio-
gram (ECG), laboratory tests, echocardiography, and according to
current guidelines [27]. During hospitalization, the patients were
treated with a vasodilator and a diuretic, with or without inotrope,
as necessary. Patients presenting with (a) an acute myocardial
infarction, (b) shock, deﬁned as hypotension requiring continuous
infusions of norepinephrine, (c) an overt infection, (d) a serum
creatinine concentration >3 mg/dl, or (e) a need for hemodialysis
or amechanical cardiac assist device ormechanical ventilatorwere
excluded from this study. We also excluded the patients who died
during the initial hospitalization, who underwent a cardiac
operation during the initial hospitalization or during the follow-
up, orwhose follow-up datawere not available (Fig. 1). The present
studywas approved by the Ethical Committee of Hyogo Prefectural
Amagasaki Hospital and conducted in compliance with the
Declaration of Helsinki.
Study measurements
After veriﬁcation of the patients’ medical histories and drug
regimens, blood samples were obtained within 6 h and 4 days after
their admission to the hospital, and analyzed for serumhemoglobin,
albumin, bilirubin, blood urea nitrogen (BUN), creatinine, Cys-C,
electrolytes, and N-terminal pro B-type natriuretic peptide. Cys-C
was measured, using the latex agglutination-turbidimetric immu-
noassay (IATRO Cys-C; Mitsubishi Chemical Medicine Corporation,
Tokyo, Japan), with a cut-off value of 1.0 mg/l. As a categorical
variable, according to the change in Cys-C, the patientswere divided
between a group in whom the Cys-C serum concentration
(a) increased between day 1 and day 4 (CysDAY 4 > DAY 1) and
(b) the Cys-C serum concentration decreased or remained un-
changed between day 1 and day 4 (CysDAY 4  DAY 1). Similarly, they
were divided between a group in whom (a) eGFR increased or
remained unchanged between day 1 and day 4 (eGFRDAY 4  DAY 1)
and (b) eGFR decreased betweenday1 and day4 (eGFRDAY 4 < DAY 1).
The primary endpoint of the study was a composite of (a)
deaths from all causes and (b) unplanned re-hospitalizations for
management of ACD.[(Fig._1)TD$FIG]
Fig. 1. Study ﬂow chart.Statistical analysis
The categorical variables are expressed as counts and
percentages and the normally distributed continuous variables
as means  standard deviation (SD). Because body mass index
and the serum concentrations of bilirubin, creatinine, Cys-C, and
N-terminal pro B-type natriuretic peptide were not normally
distributed, they were log-transformed for the analysis, and are
expressed as medians (25th to 75th percentiles). Differences in
serum Cys-C concentrations between day 1 and day 4 were
examined by Wilcoxon signed-rank test. Differences in clinical
and laboratory measurements between baseline and day 4 in
patients with CysDAY 4 > DAY 1 and patients with CysDAY 4  DAY 1
were tested by Fisher’s exact test for categorical variables and
Student’s t-test orWilcoxon rank sum test, for continuous variables,
as appropriate.
Kaplan–Meier curves were constructed to examine the effect
of changes in Cys-C and eGFR on the adverse event-free survival,
and the differences in survival rates were tested by log-rank test.
We also examined by Cox proportional hazard regression
analysis whether the association between changes in Cys-C
and event-free survival inﬂuenced the outcome of ACD indepen-
dently from other variables. Variables that emerged with a
p-value <0.10 by single variable analysis, including systolic
blood pressure, and sodium, potassium, bilirubin, inotrope use,
and CysDAY 4 > DAY 1 concentrations besides age and gender, were
entered in a multiple variable regression analysis. To ascertain
the effect of baseline renal function on the change in Cys-C
concentration, we added the concentration of Cys-C on admis-
sion to the hospital in the analysis. All analyses were two-sided,
with p < 0.05 considered statistically signiﬁcant. The analyses
were performed with the JMP1, version 10.0 software (SAS
Corporation, Cary, NC, USA).
Results
Baseline patient characteristics
We enrolled 100 patients who met the inclusion criteria and
whose characteristics are shown in Table 1. Their average age was
75 years and 53% were men.
Changes in renal function during the treatment period
The median serum Cys-C concentration increased from 1.29
(0.88–1.66) mg/l on day 1, to 1.31 (1.00–1.84) mg/l on day 4
(p < 0.001; Fig. 2). Between day 1 and day 4, the mean BUN
increased from 24  11 mg/l g/dl to 25  11 mg/l g/dl, and mean
eGFR decreased from 50  22 ml/min/1.73 m2 to 49  22 ml/min/
1.73 m2, although neither change was statistically signiﬁcant.
Baseline characteristics of patients whose Cys-C serum concentration
increased during treatment
The Cys-C concentration increased during treatment of ACD in
66 patients, from 1.09 (0.82–1.56) mg/l on day 1 to 1.25 (0.96–
1.78) mg/l on day 4. Their baseline characteristics are compared
with those of the patients whose Cys-C concentration did not
increase in Table 1. Patients in the CysDAY 4 > DAY 1 group had a
higher prevalence of atrial ﬁbrillation, a lower left ventricular
ejection fraction and higher heart rate, and were less often treated
with an angiotensin-converting enzyme inhibitor, angiotensin
receptor blocker, or a loop diuretic on admission to the hospital.
They also had lower creatinine, BUN, and Cys-C serum concentra-
tions.
Table 1
Baseline characteristics of patients grouped according to change in cystatin C.
Total (100) CysDAY 4 > DAY 1 (66) CysDAY 4  DAY 1 C (34) p
Age, years 7511 7411 7611 0.563
Women, n 47 (47) 33 (50) 14 (41) 0.526
Concomitant disorders
Ischemic heart disease, n 37 (37) 23 (35) 14 (41) 0.662
Atrial ﬁbrillation, n 252 (52) 29 (44) 23 (68) 0.034
Diabetes mellitus, n 34 (34) 24 (36) 10 (29) 0.514
Hypertension, n 78 (78) 49 (74) 29 (85) 0.308
Previous history of acute cardiac decompensation
hospitalization, n
49 (49) 27 (41) 22 (65) 0.034
Drug therapy on admission
Angiotensin-converting enzyme inhibitor or
receptor blocker, n
51 (51) 28 (42) 23 (68) 0.021
Beta-adrenergic blocker, n 41 (41) 23 (35) 18 (53) 0.091
Loop diuretic, n 63 (63) 35 (53) 28 (82) 0.005
Aldosterone blocker, n 24 (24) 15 (23) 9 (26) 0.805
Left ventricular ejection fraction, % 5017 4717 5517 0.023
Body mass index, kg/m2 244.7 234.6 254.9 0.135
Heart rate, bpm 8222 8622 7519 0.009
Blood pressure, mmHg
Systolic 13926 13926 13624 0.639
Diastolic 7918 8120 7513 0.208
Hemoglobin, g/dl 112 112.2 111.7 0.836
Albumin, g/dl 3.6 0.4 3.5 0.5 3.6 0.4 0.672
Blood urea nitrogen, g/dl 2411 2211 2711 0.007
Creatinine, mg/dl 1 [0.8–1.4] 1 [0.7–1.3] 1.2 [0.975–1.5] 0.013
Estimated glomerular ﬁltration rate, ml/min/1.73m2 5022 5322 4520 0.045
Cystatin C, mg/l 1.3 [0.9–1.7] 1.1 [0.8–1.6] 1.5 [1.2–1.9] 0.002
Sodium, mEquiv./l 1404.1 1404.1 1404.1 0.977
Potassium, mEquiv./l 4.00.6 4.0 0.6 4.00.6 0.662
Bilirubin, mg/dl 0.7 [0.6–1.1] 0.7 [0.6–1.0] 0.8 [0.7–1.3] 0.285
N-terminal pro brain natriuretic peptide, pg/ml 3118 [1723–8166] 4097 [1743–9490] 2709 [1716–6626] 0.322
Inotropes use, yes 25 (25) 16 (24) 9 (26) 0.812
Values are means SD, numbers (%) of observations or medians [ranges].
Associations were tested by Wilcoxon rank sum tests or Fisher‘s exact tests as appropriate.
Cys, cystatin C.
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Over 180 days of follow-up, 4 patients died and 26 were re-
hospitalized for management of ACD. The incidence of primary
study endpoint was lower in the CysDAY 4 > DAY 1 than in the
CysDAY 4  DAY 1 group (p = 0.040; Fig. 3A), although it was similar in
[(Fig._2)TD$FIG]
Fig. 2. Changes in cystatin C between day 1 and day 4. Comparisons ofpatients with eGFRDAY 4 < DAY 1 and patients with eGFRDAY 4  DAY 1
(p = 0.541, Fig. 3B). By single variable Cox regression analysis, high
systolic and diastolic blood pressures, high sodium and potassium,
and low bilirubin concentrations at baseline, and (a) increase in
Cys-C concentration and the absence of (b) inotrope use during
treatment were associated with low rates of primary studycystatin C were made by Wilcoxon signed-rank test (p < 0.0001).
[(Fig._3)TD$FIG]
Fig. 3. (A) Event-free survival of patientswith CysDAY 4 > DAY 1 versus CysDAY 4  DAY 1.
(B) Event-free survival of patients with eGFRDAY 4 < DAY 1 versus eGFRDAY 4  DAY 1.
Cys, cystatin C; eGFR, estimated glomerular ﬁltration rate.
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BUN, and Cys-C serum concentrations were associated with
death or re-hospitalization for ACD. Because there were only
30 events during the study period, we examined multiple
variable regression analysis in several models of different
number of covariates. High baseline sodium and an increase in
Cys-C serum concentration between day 1 and day 4 were
independent predictors of lower rates of death and re-hospitali-
zation for ACD in all models nevertheless (Table 2). Moreover,
after the addition of baseline Cys-C serum concentration to the
multiple variable regression analysis, CysDAY 4 > DAY 1 remained
an independent predictor of primary study endpoint (HR 0.362;
95% CI 0.146–0.816; p = 0.015). We also constructed the
multivariate model without Cys-C parameters but with renal
parameters such as increase in creatinine or increase in BUN or
decrease in eGFR, but no renal parameter was an independent
predictor of primary study endpoint.
Discussion
In this study, fewer patients whose blood concentration of Cys-
C increased during hospitalization for ACD died or were re-
hospitalized for management of ACD over a 180-day follow-up
than patients whose Cys-C did not increase. On the other hand, the
long-term rate of death and re-hospitalization for management of
ACD was similar in patients whose eGFR decreased or increased
during the initial hospitalization for ACD. Renal function, whetherat the time of hospitalization or at the time of discharge from the
hospital, was not a predictor of long-term clinical outcome. These
observations are in conﬂict with several recent studies, which
reported that in-hospital WRF is a predictor of adverse clinical
outcomes. Testani et al. found that aggressive ﬂuid removal was
strongly associatedwithWRF and a signiﬁcant decrease in 180-day
survival [8]. In the DOSE trial, a strategy of high-dose furosemide
administration was associated with a more abundant diuresis and
transient WRF, as well as improvements in some outcome
measures [9]. Other recent studies have reported the association
of hemoconcentration with WRF during treatment of ACD and
favorable long-term prognosis [11–13]. In the EVEREST trial,
hemoconcentration was associated with a higher incidence of in-
hospital WRF, although renal function returned to baseline within
4weeks after discharge of the patients from the hospital [13]. These
observations support the hypothesis that WRF developing during
treatment of ACD is caused by transient abnormalities in renal
hemodynamics due to vigorous decongestion, vasodilation, or
both. These studies also revealed a tendency for vigorous volume
reduction during treatment of ACD to improve the long-term
clinical outcomes. However, Metra et al. found that WRF in
patientswith signs of persistent congestionwas explained by other
pathophysiologic mechanisms than volume reduction alone and
that, in these circumstances, WRF might be associated with
adverse long-term clinical outcomes [14]. In this study, an increase
in Cys-C, although not a decrease in eGFR, was associated with a
lower long-term, event-free survival. This may reﬂect the
properties of Cys-C, which can detect changes in GFR more
reliably and rapidly than creatinine. So, recently a Japanese chronic
kidney disease guideline recommended us to estimate GFR by Cys-
C in addition to creatinine [15]. This might also mean that patients
in the CysDAY 4 > DAY 1 had undergone effective decongestion, and
were generally responsive to treatment, which is concordant with
their tendency to be less medicated with loop diuretics and to
present with a preserved renal function at the time of hospitaliza-
tion. Patients entering the hospital without a regimen of
angiotensin-converting inhibitor or angiotensin receptor blocker
can also develop in-hospital WRF, although respond favorably to
the introduction of these medications during treatment of ACD.
The prognosis of patients who develop WRF or acute kidney
injury during treatment of ACD varies depending on the threshold
that has been adopted, as they can be divided between a group that
responds to treatment of ACD and in whom the abnormalities of
renal function are transient, versus a group refractory to treatment
of ACD, in whom the hemodynamic impairment and ﬂuid overload
are major. In the latter group, the low cardiac output and high
central and renal venous pressures may lower the glomerular
ﬁltration pressure and cause WRF. This may explain the higher
incidence of atrial ﬁbrillation, lower mean left ventricular ejection
fraction, and higher heart rate at the time of hospitalization in
patients presenting with CysDAY 4 > DAY 1, whose cardiac output
may be depressed and renal function worsened.
In patients with chronic or acute heart failure, a depressed renal
function has generally been associated with a poor prognosis
[28–30], an observation conﬁrmed in studies using Cys-C [21,22].
In this study, the indices of renal function measured at the time of
admission and discharge from the hospital did not predict the
long-term prognosis, as observed in a few previous studies
[10]. We believe that this is partly explained by changes from
baseline, caused by ACD, in the indices of renal function. In some
patients, renal function preserved during the chronic phase is
depressed by transient congestion or low perfusion, while others,
whose renal function is chronically impaired, recover a relatively
better function by transient hemodilution during the hospitaliza-
tion. Therefore, the measurements made at the time of hospitali-
zation do not always reﬂect the true renal function [31]. We
Table 2
Non-adjusted and adjusted hazard ratios for all cause mortality and re-hospitalization up to 180 days.
Unadjusted analysis Adjusted analysis
HR 95% CI p Model 1 Model 2 Model 3
HR 95% CI p HR 95% CI p HR 95% CI p
Baseline characteristics
Age, per 10 years 1.142 0.828–1.716 0.453 1.058 0.716–1.660 0.792
Presence of:
Female gender 1.031 0.497–2.118 0.969 1.254 0.587–2.673 0.555
Ischemic heart disease 1.521 0.732–3.123 0.256
Atrial ﬁbrillation 1.109 0.437–1.858 0.776
Diabetes mellitus 0.933 0.419–1.949 0.858
Hypertension 1.83 0.713–6.205 0.227
Left ventricular ejection fraction,
in 10% increments
0.972 0.786–1.207 0.801
Body mass index, in 1kg/m2
increments
0.968 0.892–1.046 0.416
Heart rate, in 10bpm increments 0.883 0.710–1.070 0.214
Blood pressure, in 10mmHg
increments
Systolic 0.787 0.668–0.919 0.002 0.974 0.957–0.991 0.002 0.988 0.967–1.007 0.211 0.881 0.714–1.070 0.206
Diastolic 0.745 0.549–0.967 0.025
Hemoglobin, in 1g/dl increments 1.003 0.839–1.189 0.972
Albumin, in 1 g/dl increments 1.281 0.567–2.942 0.555
Blood urea nitrogen, in 10mg/dl
increments
0.904 0.633–1.235 0.543
Estimated glomerular ﬁltration
rate, in 10ml/min/1.73m2
increments
0.957 0.803–1.127 0.607
Log cystatin C, in 1unit
increments
1.435 0.596–3.511 0.697
Sodium, in 1mEquiv./l increments 0.892 0.828–0.966 0.006 0.887 0.818–0.965 0.006 0.877 0.807–0.958 0.004 0.877 0.806–0.956 0.004
Potassium, in 1mEquiv./l
increments
0.446 0.244–0.824 0.01 0.501 0.228–1.133 0.096 0.498 0.224–1.143 0.099
Log bilirubin, in 1unit increments 1.757 0.997–2.928 0.051 1.528 0.785–2.762 0.201 1.611 0.811–2.994 0.166
Log N-terminal pro B-type
natriuretic peptide, in 1unit
increments
1.060 0.779–1.421 0.691
Drug therapy on admission to the hospital
Angiotensin-converting enzyme
inhibitor or receptor blocker
1.803 0.872–3.922 0.113
Beta-adrenergic blocker 1.422 0.690–2.934 0.336
Diuretic 1.658 0.768–3.969 0.205
Aldosterone blocker 1.174 0.491–2.536 0.700
Drug therapy and variables
measured during
hospitalization
Inotropes use 2.280 1.069–4.690 0.034 1.815 0.792–4.062 0.156 1.823 0.800–4.049 0.150
Increase in cystatin C between
day 1 and day 4
0.481 0.233–0.991 0.047 0.470 0.228–0.971 0.042 0.426 0.199–0.900 0.026 0.415 0.193–0.885 0.023
Decrease in estimated
glomerular
ﬁltration rate between day
1 and day 4
0.797 0.374–1.638 0.539
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changes in renal function observed during treatment of ACDmight
more accurately reﬂect the patient’s long-term prognosis.
N-terminal pro B-type natriuretic peptide at the time of admission
is also known to be a strong predictor of adverse outcome in ACD
patients. In this study, high N-terminal pro B-type natriuretic
peptide value at the time of admission tended to be associatedwith
higher rate of primary endpoints but not signiﬁcantly as in other
small studies.
Limitations of the study
The association between increase in Cys-C and decreased rate of
long-term adverse clinical events indicates a correlation between
marker of WRF and favorable prognosis after ACD. This should
promote the search for newmarkers in the urine or blood to detect
true irreversible renal injury and correlate its occurrence withadverse prognosis. On the other hand, since Cys-C exerts various
biological functions, it is possible that its changes reﬂect other
pathologic processes, separate from eGFR, that inﬂuence the long-
term prognosis [32,33]. Our study was also limited by the lack of
direct measurements of GFR. If we would have systematically
followed the renal function after discharge, in-hospital WRF may
have been considered as a transient change with conﬁrmation.
Conclusion
An increase in Cys-C serum concentration during hospitaliza-
tion for management of ACDwas associated with a decreased risk
of death or re-hospitalization for ACD independently of the
baseline renal function. This observation is consistent with recent
studies, which found that in-hospital WRF based on measure-
ments of creatininewas not associatedwith an adverse long-term
prognosis.
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